Who Should Receive Neoadjuvant Chemotherapy Prior to Liver Resection for Colorectal Carcinoma Liver Metastases?
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Keith Baldwin & Ponnandai Somasundar & N. Joseph Espat
- چاپ و سال / کشور: 2011
Description
The role for neoadjuvant chemotherapy in patients with colorectal cancer liver metastases has expanded over the last 10 years. Evolution of various therapeutic modalities has occurred in the setting of an evolving and more frequent use of hepatic metastasectomy. It is clear that achieving a state of potential “resectability” is the only opportunity to obtain a cure and/or significantly extend life. Compelling evidence now exists that a neoadjuvant approach should be standard for select patients with socalled “borderline resectable” lesions. In addition, patients with initially resectable liver metastases may achieve further survival benefit from the addition of neoadjuvant treatment, with the subset of patients that obtain a complete pathologic response benefitting the most. Future neoadjuvant randomized controlled trials may further elucidate patients that will benefit from these therapeutic strategies.
Curr Colorectal Cancer Rep (2011) 7:168–174 DOI 10.1007/s11888-011-0092-3 Published online: 8 March 2011
